Chilton Capital Management LLC Increases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Chilton Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,249 shares of the medical research company’s stock after buying an additional 8,634 shares during the period. Thermo Fisher Scientific accounts for about 1.4% of Chilton Capital Management LLC’s holdings, making the stock its 17th largest holding. Chilton Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $31,105,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of TMO. Rockline Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 2.3% in the 2nd quarter. Rockline Wealth Management LLC now owns 1,329 shares of the medical research company’s stock valued at $735,000 after purchasing an additional 30 shares during the last quarter. Versor Investments LP purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $664,000. Phraction Management LLC raised its stake in Thermo Fisher Scientific by 0.6% during the 2nd quarter. Phraction Management LLC now owns 27,205 shares of the medical research company’s stock valued at $15,044,000 after acquiring an additional 172 shares during the last quarter. Verus Capital Partners LLC raised its stake in Thermo Fisher Scientific by 14.0% during the 2nd quarter. Verus Capital Partners LLC now owns 456 shares of the medical research company’s stock valued at $252,000 after acquiring an additional 56 shares during the last quarter. Finally, Resonant Capital Advisors LLC raised its stake in Thermo Fisher Scientific by 13.8% during the 2nd quarter. Resonant Capital Advisors LLC now owns 1,869 shares of the medical research company’s stock valued at $1,034,000 after acquiring an additional 227 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on TMO. Wells Fargo & Company began coverage on Thermo Fisher Scientific in a research note on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price objective for the company. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Finally, Royal Bank of Canada boosted their target price on Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $630.41.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 0.6 %

Shares of Thermo Fisher Scientific stock traded up $3.39 during trading hours on Monday, reaching $615.07. 1,058,900 shares of the company’s stock were exchanged, compared to its average volume of 1,507,780. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $622.30. The firm has a market capitalization of $234.78 billion, a price-to-earnings ratio of 39.45, a price-to-earnings-growth ratio of 2.86 and a beta of 0.77. The company has a fifty day moving average of $578.71 and a 200-day moving average of $576.22. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same quarter in the prior year, the company posted $5.15 EPS. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.